METHODS. Between 1977 and 1982, 61 patients with AML were treated with a protocol consisting of daunorubicin, vincristine, and cytosine arabinoside inducDepartment of Medicine, Division of Hematoltion followed by consolidation and maintenance for a total of 2 years. The complete ogy, University of Liège, Liège, Belgium.
very encouraging at that time. In the current study, we reanalyzed the same cohort of patients after more than 11 years of additional follow-up to examine whether the promising results observed at 6.5 years of follow-up would hold after a much longer period of observation.
PATIENTS AND METHODS
As previously published, 1 up to 2 years after diagnosis, as described previously.
1
Informed consent was obtained from the patients or their guardians. Data as of August 1, 1995, was anaAll relapsed patients died within 1.6 years at a median of 0.4 years: 6 were not reinduced, 8 died during reinlyzed and compared with the analysis performed previously on data obtained as of January 1, 1984. Actuarduction, 4 died of resistant disease, 4 died of complications while in second CR, 6 died while in second reial remission and survival analyses were performed using the Kaplan-Meier product limit method. Comlapse, and 3 died after BMT. parison between survival curves were made using the log rank test. All survival analyses were carried out
Continuous Complete Remission
At last follow-up, nine patients (23 %) had been in with Graphpad Prism software (Graphpad Software, San Diego, CA). Two patients undergoing bone marcontinuous CR: 2 were alive and well more than 17 years after CR, 1 was lost to follow-up after more than row transplantation (BMT) while in their first complete remission (CR) were censored for CR duration and 11 years, and the 2 patients who underwent BMT while in first CR were well 13 and 14 years later. However, survival at the time of transplantation.
four patients died while in CR of unrelated causes, i.e., suicide, alcoholic cirrhosis, postoperative peritonitis,
RESULTS

Complete Remission
and bladder carcinoma. The results of induction therapy were published previously. 1 Briefly, among 61 patients, 40 (66%) achieved
Duration of Response
Data analyzed as of January 1, 1984, gave a median CR CR after 1 (n Å 30) or 2 (n Å 10) courses of induction, whereas 9 (15%) died during aplasia and 12 (20%) exduration of 1.1 years, with 32% of patients projected to be still in CR at 5 years. When the data as of August perienced induction failure. CR was achieved among 84% of males versus 47% of females (P õ 0.005) and 1, 1995, were analyzed, the median CR duration did not change, but the CR rate dropped to 23% at 5 years, among 82% of patients younger than 40 years versus 59% of older patients (not significant). No other prog-18% at 10 years, and 12% at 15 years ( Fig. 1) . Although the 1984 analysis identified age 40 -60 years as a favornostic factors were identified for response. able prognostic factor for CR duration (52% at 5 years vs. 10% for younger or older patients, P Å 0.0335), the Relapses Among the 40 CR patients, 31 (78%) relapsed. Seven difference disappeared completely in the 1995 analysis. However, the significant advantage of male gender (18%) relapsed within 6 months of CR, 11 (28%) between 6 months and 1 year, 9 (23%) between 1 and 2 (median CR duration, 1.7 vs. 1.0 years, and CR rate at 5 years, 35% vs. 0%, P Å 0.0197) confirmed previous years, and 4 (10%) at 2.5, 3, 6, and 13 years, respectively. Of the 31 relapses, 25 were reinduced and 13 findings. No other prognostic factor was identified. Although a plateau of continuous remission was ap-(52%) achieved a second CR. Two of them underwent allogeneic BMT while in second relapse, and one of parent in the 1984 analysis, the occurrence of late relapses sent the curve several steps downward. them underwent allogeneic BMT while in second CR.
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03-07-97 11:25:00 cana W: Cancer same as the one reported for studies performed earlier 4 and later. [5] [6] [7] Only one other recent study, in which high dose Ara-C was used for consolidation, reported a better outcome of about 25% survival at 10 years, but only patients younger than 50 years with de novo AML were selected. 8 In our study, 18% of CR patients relapsed within 6 months, 28% between 6 months and 1 year, 23% between 1 and 2 years, and 10% after 2 years. The relapse rate was still 40% among patients who did not undergo BMT and were still in CR after 2 years, and 29% among those still in CR at 5 years. Because of relapses occurring up to 13 years after CR, the CR rate dropped from 32% at 5 years in the 1984 analysis to 23% at 5 years and only 12% at 15 years in the current FIGURE 2. Overall survival of patients in complete remission is shown. at diagnosis and late relapses caused by the overgrowth of rare drug-resistant or quiescent cells. The current study indicates that because relapses indeed Survival occur very late, a true plateau may never exist in acute Overall survival among the 61 patients was 59% at 1 nonlymphocytic leukemia (ANLL). As the existence of year, 30% at 2 years, 15% at 5 years, 10% at 10 years, a plateau is often used as an indication of cure, this and 7% at 15 years, with a median of 1.3 years. Survival observation may give the depressing message that cure of CR patients was better, with 88 %, 43%, 23%, 15%
may not be certain even after very long follow-up. and 11% survival at 1, 2, 5, 10, and 15 years, respecMore specific treatment, i.e., with monoclonal antitively, and a median of 1.7 years. Censoring for BMT bodies or differentiating agents, may thus be needed in first CR further decreased survival of CR patients to in addition to chemotherapy. 19% at 5 years, 11% at 10 years, and 7% at 15 years.
Another factor contributing to poor survival is This produced disease free survival rates of 16%, 11%, death from causes thought to be unrelated to leukemia and 7% at 5, 10, and 15 years, respectively, with a or its treatment, i.e., postoperative peritonitis, bladder median of 1.1 years. When patients dead from unrecarcinoma, alcoholic cirrhosis, and suicide, all oclated causes were censored at the time of death, overall curring within 6 years of CR. However, these deaths survival of CR patients increased to 26% at 5 years, may not be totally unrelated to leukemia, as prolonged 23% at 10 years, and 17% at 15 years (Fig. 2) . However, relative immunosuppression may cause a higher suscensoring for BMT in first CR made these values drop ceptibility to infections, chemotherapy may induce by 5%. Male gender bore a favorable prognosis as comsecondary cancers, and the strenuous experience of pared with female gender for survival of all patients leukemia and its treatment may produce or aggravate (P Å 0.0005), disease free survival (P Å 0.0239) and behavioral or psychologic disorders. Nonetheless, the overall survival of CR patients (P Å 0.0287). Other facrate of death from unrelated causes may have been tors, including age, did not show prognostic signifiparticularly high in our study and has not been reprocance for survival. duced in larger trials. Another effect of longer follow-up on the results is the disappearance of any advantage for patients age
DISCUSSION
In the current study, we updated results initially pub-40 -60 years as compared with younger or older patients. On the other hand, contrary to most other studlished in 1985, 1 with only 1 patient lost to follow-up after 11 years. Follow-up ranged from 11 to 17 years, ies, female gender remained a significant adverse prognostic factor for CR rate and duration. This was the longest published for any AML trial (a few other studies have had follow-up extending to a maximum not explained by the association of female gender with other classical adverse prognostic factors. We must of 12.5 years). The CR rate of 18% at 10 years and the overall survival of 10% at 10 years are quite similar to acknowledge that this particular finding is probably due to small numbers. However, we cannot rule out long term results from large multicenter studies performed during the same period. 2, 3 The range of 8 -15% the possibility that female gender truly is an adverse prognostic factor when patients are treated with the overall survival at 7 -10 years in these studies is the / 7b52$$0979 03-07-97 11:25:00 cana W: Cancer
